Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/02/2022* -- Results Q3 2022 -- -1.47 --
11/02/2022* 16:30 EST Earnings Call Q3 2022 -- -- --
08/03/2022 -- Results Q2 2022 -1.58 -1.58 -0.21%
08/03/2022 16:30 EST Earnings Call Q2 2022 -- -- --
05/04/2022 -- Results Q1 2022 -1.79 -1.29 -39.30%
05/04/2022 16:30 EST Earnings Call Q1 2022 -- -- --
03/01/2022 -- Results Q4 2021 6.67 4.31 54.76%
03/01/2022 16:30 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/02/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/03/2022
Beat/Miss Upgrade
Return Since -1.82%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa).
URL https://www.regenxbio.com
Investor Relations URL http://ir.regenxbio.com/
HQ State/Province Maryland
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Nov. 02, 2022 (est.)
Last Earnings Release Aug. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
11.75%
79.25%
26.17%
-2.34%
10.72%
-27.91%
2.05%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-9.34%
14.34%
-3.23%
47.78%
-78.45%
198.8%
23.35%
-21.14%
-49.20%
155.7%
-37.32%
-34.04%
-6.25%
-1.77%
224.1%
-39.25%
-38.67%
--
--
--
--
57.19%
35.27%
-33.99%
-57.25%
--
--
--
--
28.09%
434.1%
143.1%
-32.60%
As of August 12, 2022.

Profile

Edit
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa).
URL https://www.regenxbio.com
Investor Relations URL http://ir.regenxbio.com/
HQ State/Province Maryland
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Growth
Next Earnings Release Nov. 02, 2022 (est.)
Last Earnings Release Aug. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
F000016ZD9 559.00 USD 5.59%
SMHCLX 461.00 USD 4.61%
PBE 10.37M USD 3.98%
F00001DUH5 393.00 USD 3.93%
GNOM 5.467M USD 2.15%
EWSC 137614.0 USD 0.25%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter RGNX Tweets